Day: February 20, 2025

Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology

Written by Customer Service on February 20, 2025. Posted in Public Companies.

Roche’s innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, immune disorders and neurodegenerative conditions Combined with an innovative, high throughput sensor module, SBX uses expanded synthetic molecules to determine the DNA sequence of a target molecule, creating an ultra-rapid, scalable and flexible technology Reducing the time from sample to genome from days to hours, this novel approach could significantly speed up genomic research, as well as translational and clinical applications in the years to comeBasel, 20 February 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled today its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation...

Toll Brothers Announces New Home Community Coming Soon to Venice, Florida

Written by Customer Service on February 20, 2025. Posted in Public Companies.

VENICE, Fla., Feb. 20, 2025 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest Sarasota-area community, Oakbend Wellen Park, is coming soon to the Wellen Park master plan in Venice, Florida. This gated neighborhood will include a collection of spacious one- and two-story Toll Brothers home designs and an array of luxury amenities. Site work is underway, and the community is anticipated to open for sale in summer 2025. Home buyers will find a beautiful retreat close to everything at Oakbend Wellen Park. A selection of one- and two-story Toll Brothers home designs offer a range of 2,156 to over 2,900 square feet with 3 to 5 bedrooms, 2.5 to 4 baths, gorgeous outdoor living spaces, and versatile features including lofts and flex rooms. Homes are expected to be...

LEE ENTERPRISES PARTNERS WITH GARY VAYNERCHUK’S VEEFRIENDS TO PRODUCE EXCLUSIVE WEEKLY COMICS

Written by Customer Service on February 20, 2025. Posted in Public Companies.

Fun and inspiring weekly comics to make you laugh, cry, think and feelphoto of Gary VaynerchukGary Vaynerchuk (Credit: Team GaryVee)DAVENPORT, Iowa, Feb. 20, 2025 (GLOBE NEWSWIRE) — Lee Enterprises Inc, (NASDAQ: Lee) a leading provider of local news, information and advertising across 72 markets in 25 states, today announced it has entered a partnership with VeeFriends, an entertainment company created by serial entrepreneur Gary Vaynerchuk, to produce original comics that will publish weekly on weekends across Lee Enterprises’ publications. VeeFriends, which shares daily comics on Instagram and TikTok, is dedicated to creating a better world through its universe of 251 characters. Each VeeFriends character connects differently with people, reflecting their likes, passions, memories, and aspirations. “Getting...

Tarkett Participation, Tarkett’s controlling shareholder, announces its intention to file a public buy-out offer, followed by a squeeze-out, on the Tarkett shares it does not hold

Written by Customer Service on February 20, 2025. Posted in Mergers And Acquisitions.

Tarkett Participation, Tarkett’s controlling shareholder, announces its intention to file a public buy-out offer, followed by a squeeze-out, on the Tarkett shares it does not holdOffer at a price of 16 euros per share, representing a premium of 32.3% and 37.5% over respectively the volume-weighted average share price over the last 20 and 60 trading days Appointment of an ad hoc Committee comprising a majority of independent members of the Supervisory Board, and designation of Finexsi – Expert & Conseil Financier as independent expert Based on a recommendation of its ad hoc Committee, Tarkett’s Supervisory Board has favorably and unanimously welcomed the proposed public buy-out offer followed by a squeeze-outPARIS, FRANCE, February 20, 2025 – Tarkett Participation announces its intention to file in the...

Annual results 2024: Slight organic decline in sales in a persistently difficult market Growth in adjusted EBITDA and margin Strong generation of free cash flow and reduction in debt leverage

Written by Customer Service on February 20, 2025. Posted in Earnings Releases And Operating Results.

Annual results 2024: Slight organic decline in sales in a persistently difficult market Growth in adjusted EBITDA and margin Strong generation of free cash flow and reduction in debt leverage compared with December 2023 Impairment of assets in the CIS and EMEA Wood segments Results for 2024 Revenue for 2024 was slightly down compared to 2023 (-0.9%, or -0.4% at constant scope and exchange rates), reflecting the continuing slowdown in demand for flooring, particularly in EMEA and the CIS. Revenue in Q4 2024 was stable compared with 2023 (+0.1%, or -0.1% at constant exchange rates and scope of consolidation), with lower activity in Sport offset by favorable volumes in EMEA and North America. Significant improvement in adjusted EBITDA: €329 million (9.9% of sales), an increase of +€42 million (+1.3 pts) compared to 2023 Adjusted EBIT:...

Marie Brizard Wine & Spirits: Q4 2024 and full-year 2024 revenues

Written by Customer Service on February 20, 2025. Posted in Public Companies.

Charenton-le-Pont, 20 February 2025 Q4 2024 and full-year 2024 revenues 2024 revenues down 2.8%1 at €188.4 million Fourth-quarter revenues down 4.6%1 at €47.6 million, impacted by the International ClusterFrance: fourth-quarter revenues up 1.1%, and limited growth of 0.7% in full-year 2024 revenues to €83.9 million.Sales of Strategic International Brands were down, particularly William Peel in the Off-Trade business, with very high inflation in the cost of aged spirits looming as early as 2025.The fourth quarter was balanced across the board in this distribution network, all brands combined. The On-Trade market performed well over the full year, as did Agency Brands with the launch of new premium bourbon whiskey brands.International: fourth-quarter revenues down 9.0%, impacted...

GTT: Full Year 2024 Results – Record sales (+50%) and EBITDA (+65%) in a dynamic market

Written by Customer Service on February 20, 2025. Posted in Earnings Releases And Operating Results.

FY 2024 resultsRecord sales (+50%) and EBITDA (+65%) in a dynamic market€2 billion order book providing high visibility Strong growth expected in 2025Key figures for the 2024 financial year 2023 2024 Objectives 2024 2024/2023Consolidated revenues €428 M €600 – 640 M €641 M +50 %Consolidated EBITDA €235 M €345 – 385 M €388 M +65 %Proposed dividend €4.36 per share Minimum of 80% of consolidated net profit €7.50 per share +72 %HighlightsSecond record year for order intake High order book with 332 units for the core business and 50 units for the LNG as fuel business Pursuing Digital activity development with the acquisition of VPS Initial conclusions of the strategic review of Elogen’s activitiesOutlookHigh revenue visibility for...

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

Written by Customer Service on February 20, 2025. Posted in Mergers And Acquisitions.

NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) — NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. For immediate release 20 February 2025 HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) Further to the announcement on 2 January 2025 regarding the non-binding discussions for an all-share acquisition...

Coface : 2024 results: net income at €261.1m, up 8.6%, and proposed dividend at €1.40

Written by Customer Service on February 20, 2025. Posted in Earnings Releases And Operating Results.

2024 results: net income at €261.1m, up 8.6%, and proposed dividend at €1.40 Paris, 20 February 2025 – 17.35Turnover: €1,845m, down -0.6% at constant FX and perimeter and down -1.3% on a reported basisTrade credit insurance revenue decreased by -2.2% at constant exchange rates, with slightly positive customer activity in Q4-24 Client retention is still high at 92.3% but down slightly from 2023 records; pricing remained negative at -1.4%, in line with historical trends Business information once again recorded double-digit growth (+16.3% at constant FX); factoring stabilised at +0.3% with solid growth in Q4-24Net loss ratio at 35.2%, improved by 2.5 ppts; net combined ratio at 65.5%, up 1.2 pptGross loss ratio at 33.4%, improved by 2.4 ppts with still high opening year reserving and high reserve releases Net cost ratio increased...

Egetis Therapeutics to Feature MCT8 Deficiency on Behind the Mystery Airing on Lifetime in Honor of Rare Disease Day

Written by Customer Service on February 20, 2025. Posted in Public Companies.

STOCKHOLM, Feb. 20, 2025 (GLOBE NEWSWIRE) — Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX), an innovative pharmaceutical company specializing in late-stage development and commercialization of treatments for serious diseases with significant unmet medical needs in the orphan drug segment will be featured on Behind the Mystery™, a TV series in the U.S. that airs on the morning talk show The Balancing Act®. Sponsored by Egetis, this episode will raise awareness for Rare Disease Day, observed on February 28, and highlight MCT8 deficiency. Spotlighting the real-life stories of MCT8 deficiency patients and their caregivers, the episode will feature the journey to diagnosis, burden of disease and need for treatment options, along with insights from Andrew J. Bauer, MD, Endocrinologist and Medical...

Day: February 20, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals